

Instructions for Handling Test Materials and Recording Results

Samples

The 3 enclosed samples are prepared from oral fluid collected from volunteers and patients which has been heated at 60°C for 1½ hours. Nevertheless, it is recommended that laboratory personnel treat the samples with the care and attention normally exercised in handling clinical specimens. Each sample is neat oral fluid without addition of diluent buffer, however the samples obtained from known drug users may contain a small amount of the buffers encountered in oral fluid kits and occasionally a small amount (0.25%) of the non-ionic surfactant Tritox X-100 may be used to stabilise the sample. All samples contain gentamicin 0.1 g/L and penicillin 0.1 g/L as preservatives.

Samples are of 1.7ml volume. Check the code number printed on the label carefully to distinguish between the three samples. Samples should be stored at 4°C for up to 2 days or frozen if analysis is to be delayed.

Screen the samples for drugs of abuse and please follow your normal protocol when analysing the samples. The samples may be analysed directly or can be diluted first with appropriate stabilisation buffer to mimic your routine samples. Please express any quantitative findings in terms of the drug concentration present in the undiluted sample.

Please Note: Cut-offs for users of commercial kits

Participants who use commercial kits that operate to threshold concentrations different from those tabulated should report their results to those specified by the manufacture of the kit. A problem only arises in the uncommon case where the kit threshold is above the scheme threshold. In a sample containing a drug at a concentration between the two thresholds, the laboratory will receive an unsatisfactory result. When a drug is present at a concentration below the scheme threshold, no assessment is applied.

Threshold after hydrolysis

In the case of drug groups, where a sample hydrolysis step may be employed, the tabulated threshold should be taken to apply to the total sample content; free + conjugated.

Please note that as from June 2020 the SAMHSA reporting thresholds have been added to the scheme. Where there are specific SAMHSA or EWDTs reporting thresholds these are indicated in the analyte name. Where the reporting threshold is the same- just the analyte is named.

Reporting of Screening Group results

Please note that for assessment purposes:

1. All amphetamine drugs should be reported under the Amphetamine Screening Group as well as the individual screening group where that applies. E.g. MDMA and Methylamphetamine should be reported under the Amphetamine Screening Group as well as the Methylamphetamine Screening Group.
2. All benzodiazepines should be reported under the Benzodiazepine Screening Group.
3. All Opiates should be included under the Opiate Screening Group (e.g. Morphine, Codeine, Dihydrocodeine, 6-MAM) as well as the individual screening group where that applies e.g. 6-MAM.
4. Buprenorphine and Norbuprenorphine should be added together and results submitted under the Buprenorphine Screening Group.

The reporting threshold table includes the details for the relevant screening groups, however if there is any doubt please contact us for clarification.

Submission of results

This scheme allows participants to report results for screening groups and individual analytes, the options available are: detected, not detected, not tested and referred. Quantitative results may also be reported.

Reporting units

For the submission of results mass and molar units are available to participants. However, for the majority of analytes the report will be produced in mass units.

All results should be submitted using PORTAL.



DOF

Drugs in Oral Fluid Scheme

Issue No: 11

Issue Date: June 2020

Instructions for Handling Test Materials and Recording Results

Please go to <https://www.lgcpt.com/portal>

Login using your Lab ID, username and password.

PORTAL user advice has been supplied in the sample package and in the sample despatch email. Further guides can be downloaded from the help section.

Please note that this scheme utilises a screening profile. The screening profile will need to be configured on PORTAL prior to reporting results. Please refer to the quick guide sent in the sample despatch email.

Please do not hesitate to contact our support team using the details below or your local LGC representative if any difficulties are encountered.

Tel: +44 (0)161 762 2500

Email: ptcustomerservices@lgcgroup.com

Instructions for Handling Test Materials and Recording Results

Reporting thresholds

Screening tests	EWDTS µg/L	SAMHSA µg/L	Single analytes (total)	EWDTS µg/L	SAMHSA µg/L
Amfetamines screen	40		Amfetamine	15	
			Methyl-amfetamine	15	
			MDMA / MDA / MDEA Other members of the amphetamine group	15	
Amfetamine/Methamphetamine		50	Amfetamine		25
MDMA/MDA		50	Methamphetamine		25
			MDMA		25
			MDA		25
Barbiturates* screen	60	-	Specific barbiturate*	10	
Benzodiazepines screen	10	-	Specific benzodiazepines:		
			7-aminoflunitrazepam	3	
			7-amino-clonazepam	3	
			7-amino-nitrazepam	3	
			Alprazolam	3	
			Bromazepam	3	
			Clonazepam	3	
			Desmethyldiazepam (Nordiazepam)	3	
			Diazepam	3	-
			Flunitrazepam	3	
			Flurazepam	3	
			Lorazepam	3	
			Lormetazepam	3	
			Midazolam	3	
			Nitrazepam	3	
			Oxazepam	3	
			Phenazepam	3	
Temazepam	10				
Cannabinoid screen (THC)	10	4	Delta-9-THC	2	2
Cocaine and metabolites screen	30	15	Benzoylecgonine	8	8
			Cocaine	8	8
			Cocaethylene	-	-
Methadone screen EDDP screen	50	-	Methadone	20	-
			EDDP	-	-
Propoxyphene and metabolites screen	40	-	Propoxyphene or metabolite	5	-
Opiates screen	40		Morphine	15	

Instructions for Handling Test Materials and Recording Results

			Codeine	15	
			Norcodeine	2	
			6-Acetylcodeine	2	
			Dihydrocodeine	15	
Codeine/Morphine		30	Codeine		15
			Morphine		15
Hydrocodone/Hydromorphone			Hydrocodone		15
			Hydromorphone		15
Oxycodone/Oxymorphone			Oxycodone		15
			Oxymorphone		15
6-Monoacetylmorphine screen	4	4	6-Monoacetylmorphine	2	2
Buprenorphine and metabolites screen	5	-	Buprenorphine or metabolites	1	-
Phencyclidine* screen	10	10	Phencyclidine*	10	10
LSD and metabolites* screen	1	-	LSD or metabolites*	1	-

Table: The European Workplace Drug Testing Society thresholds (2015-11-02 Version 2.0).

Analytes marked with an asterisk (*) have values suggested by the scheme.

SAMHSA: Mandatory Guidelines for Federal Workplace Drug Testing Program: Final Rule, Federal Register, Vol 84, No.207, October 25, 2019; 57554-57600